Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitor

This page shows the latest PD-L1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer

Rochester, Minnesota-based Vyriad – which spun out of the Mayo Clinic – will contribute its lead drug candidate Voyager-V1 to a trial in which it will be paired with PD-L1 ... others. Meanwhile, for Merck and Pfizer the deal adds another combination

Latest news

More from news
Approximately 4 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... This deal gives Pfizer co-development and co-marketing rights to MSB0010718C, Merck KGaA's anti-PD-L1

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics